Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Boswellic acid is a pentacyclic triterpenoid compound extracted from Boswellia serrata resin that primarily inhibits 5-lipoxygenase enzyme activity. This mechanism reduces inflammatory leukotriene production and has shown potential anti-cancer effects in laboratory studies.
Origin & History
Boswellic acids are pentacyclic triterpene acids extracted from the resin of Boswellia species, particularly Boswellia sacra (frankincense trees). These compounds represent the primary active components in boswellia extracts and include four major forms: α-boswellic acid, β-boswellic acid, acetyl-α-boswellic acid, and acetyl-β-boswellic acid.
Research Narrative (Provisional)
The research dossier does not contain specific human clinical trials with PubMed PMIDs. Current evidence is primarily based on in vitro studies demonstrating mechanisms of action, including 5-lipoxygenase inhibition and apoptotic effects in cancer cell lines at 0.5 µM concentrations.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Boswellic acid is a bioactive triterpenoid compound, not a macronutrient or food source, so conventional nutritional metrics (calories, protein, fat, carbohydrates, vitamins, minerals) are not applicable. It is a collective term for a family of pentacyclic triterpenic acids extracted from the resin of Boswellia serrata and related species. Key identified compounds within this family include: acetyl-11-keto-β-boswellic acid (AKBA), the most pharmacologically potent form; 11-keto-β-boswellic acid (KBA); α-boswellic acid; β-boswellic acid; acetyl-α-boswellic acid; and acetyl-β-boswellic acid. In standardized Boswellia serrata resin extracts, total boswellic acids typically comprise 30–60% of dry extract weight, with AKBA present at approximately 3–10% of total boswellic acid content depending on extraction method. Bioavailability is notably limited due to poor aqueous solubility and low oral absorption; standard oral bioavailability of AKBA is estimated at less than 2–3% in unformulated preparations. Co-administration with a high-fat meal has been shown to increase absorption by approximately 2- to 5-fold. Phospholipid complexation (phytosome formulations) significantly enhances bioavailability. The compound acts as a pure bioactive secondary metabolite with no fiber, mineral, or vitamin content.
Reported Mechanism (Provisional)
Boswellic acid specifically inhibits 5-lipoxygenase (5-LOX) enzyme, blocking the conversion of arachidonic acid to inflammatory leukotrienes. The compound also targets multiple inflammatory pathways beyond 5-LOX, demonstrating non-steroidal anti-inflammatory activity. At 0.5 µM concentrations, boswellic acid induces apoptosis in HL-60 leukemia cells through mitochondrial-mediated cell death pathways.
Clinical Narrative (Provisional)
Current evidence for boswellic acid primarily consists of in vitro laboratory studies demonstrating 5-lipoxygenase inhibition and cancer cell apoptosis induction. The anti-inflammatory mechanism has been confirmed in cellular models, while cancer cell death effects were observed specifically in HL-60 cells at 0.5 µM concentrations. Human clinical trials examining therapeutic dosages, safety profiles, and clinical efficacy remain limited. The preliminary laboratory evidence suggests potential therapeutic applications, but more robust clinical research is needed to establish human health benefits.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.